Pamrevlumab

Pamrevlumab

Status

Phase |||

Therapeutic Approach

Combating Fibrosis

Pamrevlumab (FG-3019) targets connective tissue growth factor (CTGF), which promotes muscle fibrosis and reduces the ability of damaged muscle cells to repair. Pamrevlumab binds to CTGF and may prevent this cascade. It it thought that treatment with pamrevlumab may slow the loss of muscle function.

Status

A Phase 3 study is actively recruiting

Sponsor

This program is sponsored by FibroGen, Inc.

Related Studies

ACTIVELY
RECRUITING
LENTALOS TWO - A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
ONGOING
LELANTOS - A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
ONGOING
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects

Media Library

FEBRUARY 2022
Webinar: FibroGen DMD Pamrevlumab Phase 3 Clinical Studies Highlight
PPMD and FibroGen hosted a webinar on February 2, 2022 for a presentation discussing the clinical rationale for the use of Pamrevlumab by highlighting its Phase 2 study in non-ambulatory participants with Duchenne and provided an update on its Phase 3 094 study in ambulatory participants with Duchenne.
JUNE 2021
FibroGen Presents at the PPMD 2021 Virtual Annual Conference
Pre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library
JUNE 2019
FibroGen Presents at the PPMD 2019 Annual Conference
JUNE 2018
FibroGen Presents at the PPMD 2018 Annual Conference
OCTOBER 2017
Webinar: FibroGen Update on Pamrevlumab & Enrolling Non-Ambulatory Study
PPMD and FibroGen hosted a webinar on October 25, 2017 to hear a community update on FibroGen’s development of Pamrevlumab and enrolling FGCL-3019-079 non-ambulatory study in Duchenne.
FEBRUARY 2017
Webinar: Mission DMD: FibroGen’s Anti-Fibrosis Program
On February 1, 2017, PPMD and FibroGen hosted a webinar to discuss FibroGen’s investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is being conducted to investigate Pamrevlumab in Duchenne.

Join Our Mailing List